MediciNova Announces Closing of Underwritten Public Offering of Common Stock

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the closing of the previously announced underwritten public offering of 4,419,890 shares of its common stock at a price to the public of $9.05 per share.  The gross proceeds to MediciNova from this offering were approximately $40.0 million, before deducting the underwriting discount and other estimated offering expenses.

As quoted in the press release:

MediciNova intends to use the net proceeds received from the offering primarily to continue to fund the development of its MN-166 (ibudilast) and MN-001 (tipelukast) programs, including a Phase 3 clinical trial of MN-166 (ibudilast) for the treatment of progressive MS, and for working capital and general corporate purposes, including support for MediciNova’s continuing research and development of its product candidates and research programs, clinical trials, commercialization activities and business development activities. MediciNova may use a portion of the net proceeds for acquisitions of businesses, products, technologies or licenses that are complementary to its business, although MediciNova has no present commitments or agreements to do so.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Leave a Reply